What are COMT inhibitors?

The Parkinson’s Protocol™ By Jodi Knapp Parkinson’s disease cannot be eliminated completely but its symptoms can be reduced, damages can be repaired and its progression can be delayed considerably by using various simple and natural things. In this eBook, a natural program to treat Parkinson’s disease is provided online. it includes 12 easy steps to repair your body and reduce the symptoms of this disease. The creator of this program has divided into four segments to cover a complete plan to treat this disease along with improving your health and life by knowing everything about this health problem. The main focus of this program is on boosting the levels of hormone in your brain by making e a few easy changes in your lifestyle, diet, and thoughts

What are COMT inhibitors?

COMT inhibitors (Catechol-O-Methyltransferase inhibitors) are a class of medications used in the treatment of Parkinson’s disease, particularly in patients experiencing motor fluctuations as a result of long-term levodopa therapy. These medications work by inhibiting the COMT enzyme, which is involved in the breakdown of levodopa, the precursor to dopamine. By inhibiting this enzyme, COMT inhibitors prolong the effect of levodopa, thereby helping to manage the motor symptoms of Parkinson’s disease more effectively.

Mechanism of Action

Levodopa Metabolism: When a patient with Parkinson’s disease takes levodopa, the drug is converted into dopamine in the brain to help alleviate symptoms. However, in the periphery (outside the brain), levodopa can be broken down by the enzyme COMT into an inactive metabolite called 3-O-methyldopa. This reduces the amount of levodopa available to cross the blood-brain barrier and reach the brain.
COMT Inhibition: COMT inhibitors block the action of the COMT enzyme, preventing the breakdown of levodopa in the periphery. This results in higher levels of levodopa being available to enter the brain, which increases and prolongs its therapeutic effect. As a result, COMT inhibitors help to reduce the “wearing-off” effect that some patients experience as the effects of their levodopa dose wear off before the next dose is due.

Common COMT Inhibitors

Entacapone (Comtan)
- Use: Entacapone is typically taken with each dose of levodopa/carbidopa. It is often combined with these drugs in a single pill (e.g., Stalevo) to simplify the treatment regimen.
- Effectiveness: Entacapone is effective in reducing motor fluctuations in Parkinson’s patients, helping to smooth out the response to levodopa.
Tolcapone (Tasmar)
- Use: Tolcapone is more potent than entacapone and has a longer duration of action. However, its use is limited due to the risk of liver toxicity, and it requires regular liver function monitoring.
- Effectiveness: Tolcapone can be very effective in patients who do not respond adequately to other treatments, but its use is often reserved for those who cannot be managed with entacapone due to its side effect profile.
Opicapone (Ongentys)
- Use: Opicapone is a newer COMT inhibitor that is taken once daily. It has been shown to be effective in reducing “off” time when used with levodopa.
- Effectiveness: Opicapone offers a convenient dosing schedule with once-daily administration and has a good safety profile compared to older COMT inhibitors.

Clinical Use

Adjunct to Levodopa Therapy: COMT inhibitors are not used as monotherapy but are always combined with levodopa/carbidopa to enhance its effects. They are particularly useful for patients who experience “wearing-off” periods, where the benefits of levodopa diminish before the next dose is due.
Reduction of Levodopa Dose: By prolonging the effect of levodopa, COMT inhibitors can allow for a reduction in the total daily dose of levodopa, potentially reducing the risk of side effects like dyskinesia.

Side Effects

Dyskinesia: The most common side effect is an increase in dyskinesia (involuntary movements), as the higher availability of levodopa can exacerbate these symptoms. Adjusting the dose of levodopa can help manage this issue.
Nausea and Diarrhea: Gastrointestinal side effects, including nausea and diarrhea, are relatively common with COMT inhibitors.
Liver Toxicity: Tolcapone has been associated with a risk of severe liver toxicity, which necessitates regular liver function tests for patients on this medication.
Urine Discoloration: A harmless side effect of entacapone is the discoloration of urine to a reddish-brown color.

Conclusion

COMT inhibitors are an important tool in the management of Parkinson’s disease, particularly for patients who experience motor fluctuations with levodopa therapy. By inhibiting the breakdown of levodopa, these drugs help to prolong its effect, reducing “off” periods and improving overall symptom control. However, their use requires careful monitoring for side effects, particularly liver toxicity with tolcapone and dyskinesia with all COMT inhibitors. These medications are most effective when used as part of a comprehensive treatment plan tailored to the individual needs of the patient.

Jodi Knapp